Bolden Therapeutics Inc.

Bolden Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutic approaches for neurodegenerative diseases, particularly Alzheimer's disease (AD). Registered in SAM.gov since December 2019, the company operates as a for-profit corporate entity and has been actively pursuing federal grant awards to support its research and development efforts. The company specializes in developing novel therapeutic strategies targeting adult hippocampal neurogenesis (AHN) as a potential treatment approach for cognitive impairment and neurological conditions.

The company has secured multiple federal grant awards from the National Institute on Aging (NIA) under the Aging Research program, consistently focusing on cutting-edge research for Alzheimer's disease therapeutics. These grants, totaling approximately $504,505 for the most recent award, have supported preclinical research utilizing various therapeutic modalities including antisense oligonucleotides (ASOs) and monoclonal antibodies. Bolden Therapeutics has been developing strategies to promote neurogenesis, with specific research efforts including exon-skipping ASOs targeting neural stem cells, therapeutic antibodies designed to reduce bone morphogenetic protein (BMP) signaling, and in vitro and in vivo studies evaluating the potential of these approaches to improve cognitive function. The company's research aims to generate critical proof-of-concept data that could potentially lead to investigational new drug (IND) applications and eventual clinical development of therapies for mild cognitive impairment and Alzheimer's disease.